Allergan Q3 net earnings up

Allergan has reported net earnings attributable to the company of $179 million, or $0.58 per diluted share, for the third quarter ended September 30, 2009, compared to $165.4 million, or $0.54 per diluted share, for the third quarter ended September 30, 2008.

Operating income for the third quarter of 2009 was $236.5 million, compared to $237.4 million for the third quarter of 2008.

For the third quarter of 2009, revenues increased to $1.14 billion from $1.1 billion for the comparable quarter of 2008.

For the first nine months ended September 30, 2009, net earnings attributable to the company were $399.8 million, or $1.31 per diluted share, compared to $416.5 million, or $1.36 per diluted share, for the first nine months ended September 30, 2008.

For the first nine months of 2009, operating income was $611.1 million, compared to $612.4 million for the same period of 2008. Revenues for the first nine-month period of 2009 were $3.28 billion, compared to $3.35 billion for the 2008 period.

David Pyott, Allergan's chairman of the board and CEO, said: "We are pleased with our continued operational performance during the third quarter as our businesses are performing better than was expected at the beginning of 2009.

"With this strength in our businesses, we made the strategic decision to invest in increased Direct to Consumer advertising programs in the US as we anticipate recovery from the recession. We are also pleased that we filed, with the FDA, Botox (onabotulinumtoxinA) for chronic migraine as well as for upper limb spasticity."

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

Related terms: advertising, ceo, consumer